• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The stable emulsion contains the following components: (A) At least one perfluorocarbon compound which contains 9 to 11 carbon atoms, selected from the series comprising perfluorodecalin, perfluoromethyldecalin, perfluoroalkylcyclohexane having 3 to 5 carbon atoms in the alkyl, perfluoroalkyltetrahydrofuran having 5 to 7 carbon atoms in the alkyl, perfluoroalkyltetrahydropyran having 4 to 6 carbon atoms in the alkyl and perfluoroalkanes having 9 to 11 carbon atoms; (B) At least one perfluoro-tertiary-amine having 9 to 11 carbon atoms, selected from the series comprising perfluoro-tertiaryalkylamines having 9 to 11 carbon atoms, perfluoro-N-alkylpiperidines having 4 to 6 carbon atoms in the alkyl and perfluoro-N-alkylmorpholines having 5 to 7 carbon atoms in the alkyl; a high-molecular-weight, non-ionic surfactant having a molecular weight of 2,000 to 20,000; a phospholipoid; at least one fatty acid having 8 to 22 carbon atoms or its physiologically acceptable salt or monoglyceride; the ratio by weight of the perfluorocarbon compound (A) to the perfluoro-tertiary-amine (B) being 95-50:5-50. Such an emulsion is stable even upon prolonged storage.
    公开号:SU797546A3
    申请号:SU772447657
    申请日:1977-02-02
    公开日:1981-01-15
    发明作者:Екояма Казумаса；Яманоучи Коуичи；Мурасима Риоичиро；Цуда Есио
    申请人:Дзе Грин Кросс Корпорейшн (Фирма)；
    IPC主号:
    专利说明:

    one
    This invention relates to the medical field and relates to the preparation of an emulsion capable of carrying oxygen, which can be used as a blood substitute in mammals and as a perfusion fluid while preserving the internal organs to be transplanted.
    A method of producing an emulsion capable of carrying oxygen is known by emulsifying a perfluorocarbon compound in a physiologically acceptable medium with a particle size of 0.05-0.3 JW 13.
    However, an emulsion obtained in a known manner is not sufficiently stable during storage, the particle size changes.
    The purpose of the invention is to increase storage stability without changing the particle size.
    This goal is achieved by mixing homogeneously 40-50% (w / v) of the total amount (A) of at least one perfluorocarbon compound Cd-C, selected from the group containing perfluorodecals, perfluoromethyldexine, perfluoroalkyltetrahydro uranium Cj and perfluoroalkyltetrahydrofuran C, and ) work at least one amine perftortretichnogo Cq-C, selected from the group consisting of perfluoro N, N-dibutilmetilamin perfluoro N, m-dietilgeksilamin, perfluorotripropylamine, perfluoro N, N-dietiltsiklogeksilamin and perfluoro-N-alkylpiperidine, 2,0-5, 0% (weight // volume) sex oksietilenpolioksipro0 pilenovogo copolymer having a molecular weight of 8350-15800, or a polyoxyethylene alkyl ether having a molecular weight of 3500, 0.1 .1,0% (w / v) egg osfolipidov
    5 yolks or soybean phospholipids and 0.004-0.1% (w / v) of at least one fatty acid selected from the group containing Cf2 fatty acids and their physiologically
    0 salt and monoglyceride, when the ratio of the specified perfluorocarbon compound (A) to perfluoroctermine-amine (B) is 97-72: 8-28 by weight with the specified physiologically acceptable
    5 in aqueous medium, then emulsified by injection at a temperature up to and a pressure of 100-500 kg / cm.
    In addition, perfluoro-N-alkylpiperidine Cd-Sb is N-pentylpiperidine ft, the physiologically acceptable aqueous medium is water, Ringer's lactate solution or Ringer's solution containing glucose. In addition, a fatty acid compound is used, being a salt of an alkali metal selected from caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, palmitolic acid, oleic acid, linoleic acid and arachidonic acid, the alkali metal is potassium. The fatty acid compound is a fatty acid monoglyceride selected from caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, palmitic acid, oleic acid, linoleic acid and arachidonic acid. An emulsion is prepared isotonic with blood by adding plasma or a substance that contributes to an increase in volume, plasma, hydroxyethyl starch, modified gelatin or dextran. The emulsion is obtained in a physiologically acceptable aqueous medium of a perFluorocarbon compound capable of carrying oxygen, the particle size of which is from about 0.05 to 0.3 JW, which includes at least one perfluorocarbon compound containing 9-11 carbon atoms of the genus selected from the group consisting of perfluorodecalin, perfluoromethyldecine, perfluoroalkylcyclohexanes containing from 3 to 5 carbon atoms in the alkyl chain, perfluoroalkyl tetrahyd rofuranp containing 5 to 7 carbon atoms in the alkyl chain, perfluoroalkyl tetra hydropyrans containing from 4 to 6 atoms in the gkyl chain, perfluoroalkanes containing from 9 to 11 carbon atoms, at least one perfluorinated tertiary amine containing from 9 to 11 carbon atoms, selected from the group consisting of perfluorinated tertiary alkylamines containing from 9 to 11 carbon atoms, perfluorinated 1-alkylpiperidines containing from 4 to 6 carbon atoms in the alkyl chain, and perfluorinated N-alkylmorpholine, from 5 to 7 carbon atoms in the alkyl chain, non-ionic surfactant about high molecular weight, which varies from about 2,000 to 20,000, phosphorous lipids and at least one fatty acid compound selected from the group consisting of fatty acids containing from 8 to 22 carbon atoms, their pharmaceutically acceptable salts and their monoglycerides, wherein the ratio of said perfluorocarbon compound and said perfluorinated tertiary amine is 95-50 to 5-50 by weight. The surfactant non-ionic substance has a molecular weight of from 2000 to 20,000 and includes polyoxyethylene-polyoxypropylene copolymers, polyoxyalkyl ethers, and polyoxyethylene alkylaryl ethers. The concentration of surfactant in the emulsion is from 2.0 to about 5.0, and preferably from 3.0 to 3.5% (w / v). Examples of the perfluorocarbons having 9 to 11 carbon atoms are perfluorocycloalkanes or perftoralkiltsikloalkany which include, for example, perfluorinated Cj.5 -alkiltsiklogeksany such Kaos perftormetilpropiltsiklogeksan, perftorbutiltsiklogeksan, perftortrimetiltsiklogeksan, perftoretilpropiltsiklogeksan, and perftormetildekalin perfluorodecalin, perfluoro C alkiltetragidropiran such as perfluorohexyltetrahydropyran, perfluorinated alkyltetrahydrofurans, such as perfluoropentyltetrahydrofuran, perftorg exyltetrahydrofuran, and perfluoroheptyltetrahydrofuran, and perfluoroalkanes containing from 9 to 11 carbon atoms, such as perfluorononan and perfluorodecane. Examples of perfluorinated tertiary amines containing from 9 to 11 carbon atoms are perfluorinated tertiary alkylamines containing from 9 to 11 carbon atoms, which include, for example, perfluorotrialkylamines, such as perfluoro-1,1-dibutyl monomethylamine, perfluoro-1,1- diethylpentylamine, perfluoro-N, N-diethylhexylamine, perfluoro-N, N-dipropylbutylamine and perfluorotripropylamine, perfluorinated N, N-dialkylcyclohexylamine containing 9 to 11 carbon atoms, such as perfluoro-M, M-diethylcyclohexylshchne, tees containing 11–11 carbon atoms, such as perfluoro-M, M-diethylcyclohexylshne, and 11–11 carbon atoms, such as perfluoro-M, M-diethylcyclohexylamine, containing 11–11 carbon atoms taco as perfluoro-M-pentylpiperidine, perfluoro-N-hexy piperidine and perfluoro-M-butylpiperidine, and perfluorinated N.5-7 alkylmorpholine, such as perfluoro-N-pentylmorpholine, perfluoro-M-hexylmorpholine and perfluoro-M-pentylmorpholine; . The ratio of perfluorocarbon compound to perfluorinated tertiary amine, which is used, is 50-95 to 50-5 by weight, and the total amount contained in the emulsion is 10 to 50% (w / v). The phospholipids that are used as an emulsion-enhancing drug are the same as those commonly used for this purpose, egg yolk phosLolipid and soybean bean resilient. The amount present in the emulsion varies from 0.1 to about 1.0% (w / v) and preferably from 0.4 to 0.6% (w / v). Compound of citric acid, used as a drug that activates emulsion formation, is a fatty acid containing from 8 to 22 carbon atoms, its physiologically acceptable salt, for example, a sodium salt or potassium salt, or its monoglyceride, which includes for example, caprylic acid, caprin kialot, lauric acid, myristoic acid, palmitic acid, stearic acid, behenic acid, palmitic acid, oleic acid, linoleic acid, arachidonic acid and their sodium salts and and monoglitsoridy. These fatty acid compounds can be used individually, or as a mixture of two or more components in such a small amount that is from 0.004 to 0.1% (w / v) and preferably from about 0.02 to 0.04% (weight / volume). Among fatty acid compounds, preferred are those that contain from 14 to 20 carbon atoms and their physiologically acceptable salts, most preferred are potassium palmitate and katsh oleate, taking into account their good solubility. An emulsion capable of transporting sores is obtained by homogeneous mixing the indicated amounts of the elevated components in any order in a physiologically acceptable aqueous medium, such as distilled water, or an isotonic solution, until the initial emulsion is obtained, and then emulsified t the initial emulsion, injecting it at a temperature of up to 55 ° C through a gap under pressure of 100 to about 500 kg / cm and subjecting it to shear, obtaining a mixing effect due to a large velocity gradient, until the required particle sizes / above. The homogeneous mixing of the materials used is carried out using commonly used mixers, for example a homogeneous mixer or a propeller mixer. The emulsification is achieved by using a high pressure homogenizer, which homogenizes the mixture of two non-miscible liquids when injected through a high-pressure slit at a very high speed to achieve shear strength and mixing of liquids. A typical homogenizer is a Manton-Jau1i type homogenizer, which has a multi-way valve in combination with two or more valves, each of which has a spring inside, with which a gap is formed. In this type of homogenizer, the mixture circulates several times under a pressure of about 500 kg / cm, thereby producing a stable emulsion. The process temperature is preferably maintained from 25 to 40 ° C. The emulsion thus obtained is a dispersed phase of ultra-fine particles with a diameter of less than 0.2 I or not more than 0.3 /. It is stable without detecting an increase in particle size, even when heated or stored for a long time. Therefore, the proposed emulsion largely protects the animal, to which it is introduced, from the dangerous effects associated with the formation of agglomerates of emulsion particles. The emulsion is characterized by a long retention time in circulating. blood flow so that the amount of oxygen carried is maintained for a long time. The emulsion can be used as a fluid for transfusion after it is made physiologically isotonic, as well as in a mixture with commercial substances added to the plasma to increase its blood volume, such as dextran, ethoxylated starch and modified gelatin. It can be used as a blood substitute in mammals and as a perfusion fluid for the preservation of internal organs. Example 1. 300 g of polyoxyethylene-polyoxypropylene copolymer is dissolved in distilled WATER. on. (mol.ves.10800). 49 g of soybean phospholipids, 2 g of potassium oleate and a mixture containing 3 kg of perfluorodecalin and 300 g of perfluorotripropylamine are added to the solution. The resulting mixture is stirred in a mixer until the initial emulsion is obtained. The obtained initial emulsion is loaded into the reservoir for the liquid of the injection emulsifier, and an emulsion of npv is obtained by passing it 12 times through a valve under pressure from 200 to 30% kg / cm, while the temperature of the liquid is kept within 1 ± 35 ° C. The semi-enamel emulsion contains 30.5% (w / v) perfluorodecalin and 2.9% (w / v) perfluorotripropylamine. The average particle diameter is from 0.09 to 0.1 / according to the centrifuge sedimentation method. The emulsion practically does not detect an increase in particle size when it is placed in an ampoule for injection and is subjected to thermal sterilization at 115 ° C for 12 minutes in a specially designed rotary sterilizer. Table 1 shows the distribution of particle sizes of this emulsion and
    particle size distribution for an emulsion of perfluorodecalin alone, prepared without the use of perL-tertropylamine.
    As can be seen from Table 1 during storage for 6 months in the emulsion, no agglomerates were formed, and the size of its particles remained almost unchanged.
    Example 2. 330 g of polyoxyethylene octyl ether {average mol. Weight 3500) are dissolved in 8 l of distilled bath water. 4Q g of soybean phospholipid and 2 g of potassium oleate are added to the solution, the mixture is stirred in a mixer until a dispersion is obtained, a mixture of 3 kg of perfluoromethyldecalin and 600 g of perfluoro-N-pentylpiperidine is added to the dispersion, and the mixture is mixed and the original emulsion. The original emulsion is thoroughly emulsified by the same procedure as in Example 1, and the resulting emulsion is placed in small ampoules. The emulsion in the ampoule is subjected to heat sterilization at IIS-C for 12 minutes in a rotary sterilizer. The emulsion contains 29.7% (w / v) perfluoromethyldecalin and 8% (w / v) perfluoro-M-pentyl piperchidine.
    Table 1 shows the particle size distribution after sterilization and the average particle diameter after storage at a period of 6 months, as well as dan for the comparison emulsion obtained from perfluorodecalin alone.
    Example 3. 100 g of polyoxyethylene-polyoxypropylene copolymer with an average molecular weight of 8350 is dissolved in distilled water. To the resulting solution, 20 g of egg yolk phospholipids and 0.5 g of oleic acid are added, and then the mixture is stirred in a mixer until dispersion. A mixture of 640. g of perfluorodecalin and 250 g of perfluorobutyl monomethylamine is added to the dispersion, and the resulting mixture is mixed in a mixer until the initial emulsion is obtained. Then, the original emulsion was emulsified according to the procedure of Example 1 and sterilized by heating at 115 ° C for 12 minutes in a rotary sterilizer. The emulsion contains 25.3% (w / v) perfluorodecalin and 9.8% (w / v) perfluorodibutyl mono methylamine. The average particle diameter and particle size distribution of the proposed emulsion and the known emulsion)
    obtained from only one perfluoro decalin, are given in table 1. Table 1 shows the average particle diameter of the proposed emulsion after storage at 4 ° C for 6 months.
    Example. 4. Dissolve 35 g in 800 ml of distilled water.
    polyoxyethylene-polyoxypropylene copolymer with an average molecular weight of 15,800. To the solution, 4 g of egg yolk phospholipids and 0.1 g of lauric monoglyceride are added, and the mixture is stirred in a mixer until a dispersion is obtained. . A mixture of 350 g of perfluorohexyltetrahydropyran and 40 g of perfluoro-N, M-diethylcyclohexylamine is added to the dispersion, and the mixture is mixed in a mixer until the initial emulsion is obtained. The original emulsion is emulsified further according to the procedure of Example 1 and the resulting emulsion is divided into small doses, which are placed in ampoules. The emulsion contained in the ampoule is subjected to heat sterilization at 12 minutes in a rotary sterilizer. The emulsion contains 35.7% (w / v) perfluorohexyltetrahydropyran and 4.1% (w / v) operfluoro-N, N-diethylcyclohexylamine.
    The average particle diameter of this emulsion is the same as the sample for comparison of the emulsion obtained with IC. using only perfluorohexyltetrahydropyran, after sterilization are shown in table 1. The emulsion obtained by the method of this example does not change the particle size after storage at 4 ° C for 6 months.
    Example 1 (experimental). A test for mixing with a substance used to increase plasma volume in the blood.
    For clinical use, the proposed emulsion is preferably used in combination with the branch used to increase plasma volume to compensate for insufficient oncotic pressure. When mixing an emulsion with a substance used to increase the volume of the plasma, reversible blistering, which may be caused by the interaction between the two colloidal solutions, is not observed.
    The emulsions used in this experiment are perfluorodecalin and perfluoro-M, H-dibutylmethylamine (5: 2) emulsions of various concentrations, prepared in the same manner as in Example 3 (polyoxyethylene polyoxypropylene copolymer 3.4% (w / v) , egg yolk phospholigids 0.6% (w / v) potassium oleate 0.04% (w / v) and for comparison take perfluorodecine emulsions of various concentrations, obtained in accordance with a known method (egg yolk phospholipid 4% (weight / volume), potassium rleate 0.02% (weight / volume). Each emulsion is made isotone using lactated Ringar or Krebs-Ringer bicarbonate solution, then mixed with a substance to increase plasma volume, so that the final concentration of the latter reaches from 1 to 6% (w / v) and 6 hours after mixing at room temperature, the formation of sediment The following substances are used to increase plasma volume: ethoxylated starch (OEK), average molecular weight 200000, 20% (weight / volume) in physiological solution and Dextran 40, average molecular weight 40,000, 10% (weight / volume) in Physi Oologichek water solution.
    The results obtained are presented in Tables 2 and 3.
    From the results obtained it can be seen that the proposed emulsion is much less affected by the presence of the substance used to increase the volume of the plasma than by the emulsion obtained in a known manner. The proposed emulsion can be mixed with Dext "wound 40 and OEC drugs in any ratio to achieve physiological colloidal isotonicity, which is obtained by adding Dextran 40 and OEC in the final concentration of 2% (w / v) and 3% (w / v), respectively .
    Results similar to those indicated above were also obtained for the emulsions obtained in Examples 1, 2, and 4.
    Example 2 (experimental). To assess the effectiveness of the emulsion, a study of exchange rate in rats was carried out.
    In this experiment, two types of emulsion are used: the emulsion obtained in Example 3 and the emulsion obtained in a known manner.
    The composition of both emulsions is given in table 4.
    To accomplish electrolytic and colloidal isotonicity, one volume of the hypertonic electrolytic solution listed in Table 4 is added to 9 volumes of the emulsion, and then 1 volume of the resulting emulsion containing electrolytes is mixed with 3 Volumes of 6% ethoxylated starch (molecular weight 40,000 -50000) in Ringer's lactate solution or for comparison in rat plasma, before use.
    Rats weighing from 200 to 250 g alternately transfuse the emulsion containing electrolytes and ethoxylated starch or plasma by repeated bleeding from the carotid artery and infusion instead of a hematocrit of 1.4% and 7%, respectively, at a pressure of 100% oxygen in 1 atm
    The life time of the rats subjected to alternate overflow is then determined.
    The results are shown in table.5.
    As follows from .tab.5, the proposed emulsion is more effective in saving the life of an animal with abundant blood loss compared to a known emulsion.
    Primer (experimental). The emulsion obtained in example 3, and the emulsion obtained in a known manner, is subjected to the test
    5 on the degree of toxicity.
    To make the emulsion is isotonic, 1 volume of electrolytes is added to 9 volumes of the emulsion just before use. CoO becoming these emulsions is given in table 4. Male rats of the urstar race weighing from 100 to 120 g were used as experimental animals. Rats were injected intravenously with an emulsion and their survival was observed for several weeks after the injection. The results are shown in table 6.
    As follows J1.3 of the tab. 6, the lethal 40 dose of the dose for both emulsions was about 130 ml / kg of live weight, which indicates their very low toxicity.
    The proposed method allows to obtain an emulsion capable of transferring oxygen that is stable during storage without changing the particle size.
    oh oh
    Tf
    about
    V v
    1 2 3
    4 5 6
    Example
    - without precipitation;
    + with the formation of sediment
    Fluorocarbon Perfluorodecalin 25.3
    PPFluorodibutylmonomethylamine9, 8
    PLVP Phospholipid
    egg yolk3,4
    table 2
    Table
    + + + + +
    + +
    + + +
    + +
    + +
    Table 4
    28
    PH
    Note Values obtained for 5 rats in
    Continued table. four
    8.0
    6.0
    Table 5.
    like a group.
    Lozhen10 / 1010/10 10/1010/1010/10 87
    10/1010/10 9/109/109/10
    100
    10/109/10 8/108/107/10 115
    9/108/10 6/106/106/10 132
    6/104/10 3/103/101/10 152
    10/1010/10 10/101/1010/10
    known 87
    10/1010/10 9/109/109/10 100
    10/109/10 9/107/107/10 115
    权利要求:
    Claims (4)
    [1]
    9/108/10 7/106/105/10 1327/106/10 4/103/101/10 152 Claim 1. Method for producing an emulsion capable of carrying oxygen by emulsifying a perfluorocarbon compound in a physiologically acceptable medium with a particle size of 0.050, 3ju, characterized in that, in order to increase storage stability without changing the particle size, 40-50% (weight / volume) of the total amount (A) of at least one perfluorocarbon compound Cd-C, selected from the group containing perfluorodecalin, perfluoromethyldecalin, perfluoroalkyltetrahydrof wounds Su and perfluoroalkyltetrahydrofuran C and {B); at least one perfluorotretic amine Cd-C selected from the group consisting of perfluoro M, M-dibutylmethlamine, perfluoro N, M-diethylhexylamine, perfluorotripropylamine, perfluoro N, №-diethylcyclohexylamine and perfluoro-N-alkylpiperidine, 2,05 (w / v) polyoxyethylene polyoxypropylene copolymer having a molecular weight of 8350-15800, or polyoxyethylene alkyl ether having a molecular weight of 3500, 0.1-1,
    T a, blitz 6
    135
    131 (w / v) egg yolk or soy phospholipid phospholipids and 0 0040, 1% (w / v) of at least one fatty acid selected from the group consisting of C fatty acids and their physiologically acceptable; salts and monoglycerides, with a ratio | said perfluoroctert-amine perfluorocarbon compound (A) (c) 92-72: 8-28 by weight with said physiologically acceptable aqueous medium, then emulsified by injection at a temperature up to and pressure of 100-500 kg / cm.
    [2]
    2. A process as defined in claim 1, wherein perfluoro-N-alkylpiperidine C4-C is H-pentylpiperidine.
    [3]
    3. Method POP1, characterized in that the physiologically acceptable aqueous medium is water, Ringer's lactate solution or Ringer's solution containing glucose.
    [4]
    4. Method POP.1, characterized in that a compound is used which is an alkaline salt of a fatty acid selected from caprylic acid, capric acid, lauric acid.
    21 .79754622
    myristic acid, palmitic palmitolic acid, oleic acid, acid, stearic acid, running lots, linoleic acid and arachidonic acid, palmitic acid, howl acid.
    oleic acid, linoleic acid6. Method pop. 1, distinguishing arachidonic acid, with alkalis and the fact that the emulsion is prepared
    Potassium is the metal. isotonic with blood pu5. The method according to claim 1, characterized by the addition of bleach or substances
    u and with the fact that the compound oily contributing to the increase in
    the acid is a monoglyplasma, is a hydroxyethyl starch, a fatty acid modicride, a selected gelatin or dextran.
    caprylic acid, capric acid. Sources of information,
    lauric acid, myristic acid taken into account during examination,
    acid, palmitic acid, stea-1. For Japan 22b12, cl. B 01 F,
    rinic acid, behenic acid, 1973.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU797546A3|1981-01-15|Method of producing emulsion capable of oxygen transfer
    US4252827A|1981-02-24|Oxygen-transferable fluorocarbon emulsion
    AU629832B2|1992-10-15|Improved emulsions of highly fluorinated organic compounds
    US3962439A|1976-06-08|Oxygen-transferable emulsion
    US3993581A|1976-11-23|Process for preparing stable oxygen transferable emulsion
    AU598226B2|1990-06-21|Stable emulsions of highly fluorinated organic compounds
    JP5668004B2|2015-02-12|Aqueous pharmaceutical composition of 2,6-diisopropylphenol | and use thereof
    US4423077A|1983-12-27|Perfluorochemical emulsion artificial blood
    CN103313729B|2016-11-09|O/W type Emulsion including semifluorinated alkane
    EP0220153B1|1991-07-24|A nutritive emulsion having oxygen-transporting properties, and process for its preparation
    US4970209A|1990-11-13|Fat emulsions
    US5684050A|1997-11-04|Stable emulsions of highly fluorinated organic compounds
    Geycr1988|Perfluorochemicals as oxygen transport vehicles
    RU2393849C2|2010-07-10|Medical emulsion of perfluororganic compounds, method of preparation and method of application
    BG106446A|2002-09-30|Parenteral cisplatin emulsion
    RU2070033C1|1996-12-10|Method of preparing perfluorocarbon emulsion for medicinal aims
    KR810000695B1|1981-06-22|Process for preparing flurocarbon emulsions capable of carrying oxygen
    RU2162692C1|2001-02-10|Composition based on perfluoroorganic compound emulsion for medical-biological aims
    RU2631608C1|2017-09-25|Highly-dispersive emulsion based on perfluororganic compounds with gas transportation properties
    EP0440925A1|1991-08-14|Internal organ-preserving liquid and method for preserving internal organs
    US5262442A|1993-11-16|Process for rapid thawing and storage of frozen fluorocarbon emulsion, and resultant product
    RU2745290C2|2021-03-23|Emulsion of perfluorocarbon compounds for biomedical purposes and a method for its production
    US20210283071A1|2021-09-16|Preparation of a single-surfactant microemulsion
    JPH09502173A|1997-03-04|Ultrasound contrast agent
    JP2722416B2|1998-03-04|Improves brain tumor internalization
    同族专利:
    公开号 | 公开日
    NO770324L|1977-08-04|
    CA1072446A|1980-02-26|
    DK307276A|1977-08-04|
    DK152256C|1988-08-29|
    SE7607727L|1977-08-04|
    IL51325D0|1977-03-31|
    ATA496676A|1979-07-15|
    FI770354A|1977-08-04|
    FI58071B|1980-08-29|
    IL51325A|1980-05-30|
    NO145370C|1982-03-10|
    DE2630586A1|1977-08-11|
    ZA77229B|1977-11-30|
    AT355214B|1980-02-25|
    AR218864A1|1980-07-15|
    ES449635A1|1977-11-16|
    LU76698A1|1977-06-28|
    NL171533C|1983-04-18|
    FR2361867B1|1978-12-15|
    CH633674A5|1982-12-31|
    FI58071C|1980-12-10|
    NO145370B|1981-11-30|
    DD132231A5|1978-09-13|
    SE442706B|1986-01-27|
    NL7607514A|1977-08-05|
    DK152256B|1988-02-15|
    JPS5296722A|1977-08-13|
    BE850992A|1977-05-31|
    AU1550576A|1977-07-28|
    GB1549038A|1979-08-01|
    DE2630586C2|1984-06-07|
    NL171533B|1982-11-16|
    NZ183096A|1979-04-26|
    FR2361867A1|1978-03-17|
    JPS5835485B2|1983-08-03|
    MX4136E|1982-01-06|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1997025978A1|1996-01-15|1997-07-24|BELOYARTSEV, Arkady Felixovich|Method of obtaining perfluorocarbon emulsions for medical purposes|
    WO2005089739A1|2004-03-01|2005-09-29|Germanov, Evgeny Pavlovich|Medical emulsion of perfluororganic compounds and method for the production thereof|
    WO2007105978A1|2006-03-14|2007-09-20|Sergey Ivanovich Vorobyev|Perfluorocarbon gas transferring emulsion for medico-biological use, the composition and the production method thereof a medicinal agent|
    EA022379B1|2007-12-22|2015-12-30|Виваселле Био, Инк.|Method of treating hypovolemia, ischaemia and haemorrhagic shock in mammals|
    RU2745290C2|2019-04-12|2021-03-23|Ирина Николаевна Кузнецова|Emulsion of perfluorocarbon compounds for biomedical purposes and a method for its production|CH604490A5|1970-09-05|1978-09-15|Green Cross Corp|
    JPS5331209B2|1973-10-05|1978-09-01|US4186253A|1978-10-10|1980-01-29|The Green Cross Corporation|Perfusate for preserving organ to be transplanted and preserving method|
    JPS617171B2|1979-01-25|1986-03-04|Toshiro Wada|
    DE3277769D1|1981-09-08|1988-01-14|Green Cross Corp|Perfluorochemicals, process for preparing the same and their use as blood substitutes|
    US4423077A|1982-07-27|1983-12-27|The University Of Pennsylvania|Perfluorochemical emulsion artificial blood|
    JPS6360006B2|1982-09-09|1988-11-22|
    JPH0412244B2|1983-03-24|1992-03-04|Tetsuzo Agishi|
    WO1993002653A1|1991-08-08|1993-02-18|Segel Leigh D|Fluorocarbon blood substitute|
    US5502094A|1994-05-20|1996-03-26|Minnesota Mining And Manufacturing Company|Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use|
    US5658962A|1994-05-20|1997-08-19|Minnesota Mining And Manufacturing Company|Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application|
    CN1068778C|1998-05-15|2001-07-25|赵超英|Novel drug composition for treating and curing and its preparing method|
    US7357937B2|2002-09-24|2008-04-15|Therox, Inc.|Perfluorocarbon emulsions with non-fluorinated surfactants|
    GB2467353B|2009-01-30|2011-07-20|Steven Skill|Apparatus for treatment of fluid streams and method of conducting the same|
    ES2541226B2|2014-01-15|2016-02-12|MONDRAGÓN GOI ESKOLA POLITEKNIKOA J. Mª. ARIZMENDIARRIETA, S.C|Blood phantom|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US65496476A| true| 1976-02-03|1976-02-03|
    [返回顶部]